Twitter  |    LinkedIn

CAR-T Cells as a Therapy for γδ T-cell Cancers

CAR-T Cells as a Therapy for γδ T-cell Cancers

This Dermatology Innovation Leadership Think Tank meeting featured Christoph Ellebrecht, MD and Aimee Payne, MD, PhD, of University of Pennsylvania, as they discuss Chimeric antigen receptor (CAR) T cells as a precision curative therapy for gamma-delta T cell cancers.

The University of Pennsylvania’s successes in treating cancer with CAR T cell therapy represent two decades of investment in the people and infrastructure to advance these novel cellular immunotherapies to clinical trials. Clinician-scientists of all disciplines and in every career stage are now empowered to harness the immune system to treat more cancers, as well as other immune diseases.

Webinar Takeaways:

  • Understand how chimeric antigen receptor technology harnesses the immune system’s power to induce lasting remissions of previously refractory B cell leukemias and lymphomas.
  • See how breakthrough discoveries in B cell-mediated cancers have led to innovative approaches for B cell-mediated autoimmune diseases that may offer similar potential for lasting remission.
  • Learn how novel CAR technologies can provide opportunity to impactfully treat and potentially cure a breadth of gamma-delta T cell leukemias and lymphomas.

Who Should Attend?

  • Physicians
  • Scientists
  • Investors
  • Product Development Organizations
  • Government Officials & Regulators
  • Patient Advocacy Organizations



Aimee Payne, MD, PhD.

Penn Medicine’s Aimee Payne, MD, PhD, continues to re-define this field. Dr. Payne is Professor of Dermatology and Director of the Penn Clinical Autoimmunity Center of Excellence at the University of Pennsylvania. She is also co-founder and co-chair of the Scientific Advisory Board at Cabaletta Bio (NASDAQ:CABA), focused on targeted cellular immunotherapies of B cell-mediated diseases. Her group invented a precision cellular immunotherapy for autoimmunity known as DSG3-CAART, which is being evaluated in a first-in-human clinical trial that launched in 2020.

Christoph Ellebrecht, MD.

Christoph Ellebrecht, MD, rising Clinical Instructor of Dermatology and co-inventor of DSG3-CAART, is now expanding CAR-T technology to create one of the few programs targeting gamma-delta T cell cancers, a rapidly lethal group of cancers notoriously refractory to current chemotherapeutic approaches. Targeting the gamma-delta T cell receptor with CAR T cells offers a potentially curative therapy for this devastating group of cancers with high unmet need for effective treatments.